• For the latest updates on our ongoing response to COVID-19, please click here.

    Our Purpose


    About


    Science & Medicine


    News and Press


    Company Statements

    Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir

    Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims

    Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China

    Gilead Sciences Response to Médecins Sans Frontières

    Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation

    Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak

    Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials

    Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents

    Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)

    Gilead Statement on Commitment to Advancing Descovy for PrEP? Study in Cisgender Women & Adolescent Females

    Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents

    Petitions to US Patent and Trademark Office on HIV PrEP Patents

    Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy

    Grants for SCLAN

    Authorized Generics For HCV

    Discount For Ambisome

    Gilead 2017 Year in Review

    100 Corporate Equality Score

    Emergency Disaster Response

    Gilead Year in Review 2016

    Top Corporate Philanthropist

    HIV Medicines Reach 10 Million People

    Discover Study Of FTAF For PrEP

    Corporate Responsibility Report 2015

    Gilead Supports PrEP Education

    Corporate Contributions Report

    Celebrating Transgender Awareness Week

    Kite Pharma

    Harnessing The Immune System

    Careers


    Utility


    Global Operations


    在线aⅴ自拍在线偷拍视频